Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Influence of peritoneal dialysate flow rate on the pharmacokinetics of cefazolin.

Manley HJ, Bridwell DL, Elwell RJ, Bailie GR.

Perit Dial Int. 2003 Sep-Oct;23(5):469-74.

PMID:
14604200
2.

Pharmacokinetics of intraperitoneal cefazolin and ceftazidime coadministered to CAPD patients.

Elwell RJ, Manley HJ, Frye RF, Bailie GR.

Int J Artif Organs. 2005 Aug;28(8):808-16.

PMID:
16211531
3.

An in vivo-in vitro study of cefepime and cefazolin dialytic clearance during high-flux hemodialysis.

Maynor LM, Carl DE, Matzke GR, Gehr TW, Farthing C, Farthing D, Brophy DF.

Pharmacotherapy. 2008 Aug;28(8):977-83. doi: 10.1592/phco.28.8.977.

PMID:
18657014
4.

Pharmacokinetics of intermittent intraperitoneal cefazolin in continuous ambulatory peritoneal dialysis patients.

Manley HJ, Bailie GR, Asher RD, Eisele G, Frye RF.

Perit Dial Int. 1999 Jan-Feb;19(1):65-70.

PMID:
10201343
5.
6.

Correlation of intraperitoneal antibiotic pharmacokinetics and peritoneal membrane transport characteristics.

Elwell RJ, Bailie GR, Manley HJ.

Perit Dial Int. 2000 Nov-Dec;20(6):694-8.

PMID:
11216561
7.

Pharmacokinetics of intermittent intravenous cefazolin and tobramycin in patients treated with automated peritoneal dialysis.

Manley HJ, Bailie GR, Frye R, Hess LD, McGoldrick MD.

J Am Soc Nephrol. 2000 Jul;11(7):1310-6.

8.

Vancomycin disposition following intraperitoneal administration in children receiving peritoneal dialysis.

Blowey DL, Warady BA, Abdel-Rahman S, Frye RF, Manley HJ.

Perit Dial Int. 2007 Jan-Feb;27(1):79-85.

PMID:
17179516
9.

Intraperitoneal cefazolin and ceftazidime effects on human peritoneal mesothelial cell release of cancer antigen-125.

Manley HJ, Elwell RJ, Bailie GR, Welch CL.

Ann Pharmacother. 2004 Dec;38(12):2035-40. Epub 2004 Nov 9.

PMID:
15536141
10.

Impact of fill volume on peritoneal clearances and cytokine appearance in peritoneal dialysis.

Paniagua R, Ventura Mde J, Rodríguez E, Sil J, Galindo T, Hurtado ME, Alcántara G, Chimalpopoca A, González I, Sanjurjo A, Barrón L, Amato D, Mujais S.

Perit Dial Int. 2004 Mar-Apr;24(2):156-62.

PMID:
15119636
11.

The role of tidal peritoneal dialysis in modern practice: A European perspective.

Vychytil A, Hörl WH.

Kidney Int Suppl. 2006 Nov;(103):S96-S103. Review.

PMID:
17080119
12.

The alteration of dialysate cancer antigen 125 concentration under a biocompatible bicarbonate peritoneal dialysis solution and the preservation of the mesothelial cell viability.

Theodoridis M, Passadakis P, Kriki P, Gioka T, Panagoutsos S, Mourvati E, Thodis E, Kantartzi K, Vargemezis V.

Ren Fail. 2008;30(2):161-7. doi: 10.1080/08860220701808384.

PMID:
18300115
13.

Effects of interleukin-6 T15A single nucleotide polymorphism on baseline peritoneal solute transport rate in incident peritoneal dialysis patients.

Hwang YH, Son MJ, Yang J, Kim K, Chung W, Joo KW, Kim Y, Ahn C, Oh KH.

Perit Dial Int. 2009 Jan-Feb;29(1):81-8.

PMID:
19164257
14.

Intraperitoneal pressure in PD patients: relationship to intraperitoneal volume, body size and PD-related complications.

Dejardin A, Robert A, Goffin E.

Nephrol Dial Transplant. 2007 May;22(5):1437-44. Epub 2007 Feb 17.

PMID:
17308323
15.

Systemic and intraperitoneal interleukin-6 system during the first year of peritoneal dialysis.

Pecoits-Filho R, Carvalho MJ, Stenvinkel P, Lindholm B, Heimbürger O.

Perit Dial Int. 2006 Jan-Feb;26(1):53-63.

PMID:
16538876
16.

Determinants of peritoneal solute transport rates in newly started nondiabetic peritoneal dialysis patients.

van Esch S, Zweers MM, Jansen MA, de Waart DR, van Manen JG, Krediet RT.

Perit Dial Int. 2004 Nov-Dec;24(6):554-61.

PMID:
15559485
17.

Treatment of peritonitis in APD: pharmacokinetic principles.

Manley HJ, Bailie GR.

Semin Dial. 2002 Nov-Dec;15(6):418-21. Review.

PMID:
12437537
18.

The impact of various cycling regimens on phosphorus removal in chronic peritoneal dialysis patients.

Juergensen P, Eras J, McClure B, Kliger AS, Finkelstein FO.

Int J Artif Organs. 2005 Dec;28(12):1219-23.

PMID:
16404697
19.

Impact of new dialysis solutions on peritonitis rates.

Ahmad S, Sehmi JS, Ahmad-Zakhi KH, Clemenger M, Levy JB, Brown EA.

Kidney Int Suppl. 2006 Nov;(103):S63-6.

PMID:
17080113
20.

Impact of ACE inhibitors and AII receptor blockers on peritoneal membrane transport characteristics in long-term peritoneal dialysis patients.

Kolesnyk I, Dekker FW, Noordzij M, le Cessie S, Struijk DG, Krediet RT.

Perit Dial Int. 2007 Jul-Aug;27(4):446-53.

PMID:
17602154

Supplemental Content

Support Center